For some of us working around obesity and metabolic disease, this feels like a long‑awaited course correction. For years we have argued that simple weight or BMI is a very crude proxy for risk, and that the real damage comes from the chronic inflammatory and metabolic derangement that excess adiposity can drive, rather than from the kilograms themselves. What this OBSCORE work shows, using large real‑world datasets, is that a small set of routine clinical markers – many of which reflect underlying inflammatory and metabolic stress – predicts future obesity‑related complications far better than BMI or traditional scores. In practice it shifts the focus from “how heavy are you?” to “how metabolically inflamed and fragile are you?”, and it explains why two people with the same BMI can have completely different long‑term risk.

The same logic shows up in other chronic inflammatory conditions. Population studies, including large registry‑based cohorts, show that people with ankylosing spondylitis have about a 30–50% higher risk of major cardiovascular events (acute coronary syndromes, stroke, thromboembolism) than matched controls, even after adjusting for age and sex. That excess risk is not explained by body size alone, but by the chronic inflammatory milieu and its impact on vascular biology and conventional risk factors. Taken together, these lines of evidence support a shift from a weight‑centric model of risk to an inflammation‑ and metabolic‑health‑centric model across a range of conditions.

The challenge, of course, is that an inflammation‑centric strategy naturally points towards low‑cost generic agents and lifestyle interventions, whereas much of the commercial momentum in this arena is behind newer, high‑cost biologic and metabolic therapies. It will be important that tools like OBSCORE are used to support mechanism‑based, cost‑conscious care, rather than simply to channel more patients towards the most expensive end of the therapeutic spectrum.